Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
du Bois, 2005, 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004), Ann Oncol, 16, viii7, 10.1093/annonc/mdi961
Bookman, 2009, Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup, J Clin Oncol, 27, 1419, 10.1200/JCO.2008.19.1684
Hoskins PJ, Vergote I, Stuart G, et al. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. 2008 ASCO Annual Meeting; Chicago, IL USA; May 30–June 3, 2008. Abstract LBA5505.
Lopes, 1993, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines, Cancer Chemother Pharmacol, 32, 235, 10.1007/BF00685842
Jordan, 1996, Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death, Cancer Res, 56, 816
Katsumata N, Watanabe T, Mukai H, et al. A phase II trial of weekly paclitaxel/carboplatin (TJ) as salvage chemotherapy in patients with relapsed ovarian cancer. 2001 ASCO Annual Meeting; San Francisco, CA, USA; May 12–15, 2001. Abstract 865.
Rose, 2005, A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma, Gynecol Oncol, 96, 296, 10.1016/j.ygyno.2004.03.046
Sehouli, 2008, Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO, Cancer Chemother Pharmacol, 61, 243, 10.1007/s00280-007-0466-z
Yedema, 1992, Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas, Tumour Biol, 13, 18, 10.1159/000217748
Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014
Shepherd, 1989, Revised FIGO staging for gynaecological cancer, Br J Obstet Gynecol, 96, 889, 10.1111/j.1471-0528.1989.tb03341.x
Calvert, 1989, Carboplatin dosage: prospective evaluation of a simple formula based on renal function, J Clin Oncol, 7, 1748, 10.1200/JCO.1989.7.11.1748
Jelliffe, 1973, Letter: Creatinine clearance: bedside estimate, Ann Intern Med, 79, 604, 10.7326/0003-4819-79-4-604
Rustin, 2006, Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide, J Clin Oncol, 24, 45, 10.1200/JCO.2005.01.2757
National Cancer Institute. Cancer Therapy Evaluation Program: common toxicity criteria, version 2.0. DCTD, NCI, NIH, DHHS, 1998.
Norton, 2001, Theoretical concepts and the emerging role of taxanes in adjuvant therapy, Oncologist, 6, 30, 10.1634/theoncologist.6-suppl_3-30
Sparano, 2008, Weekly paclitaxel in the adjuvant treatment of breast cancer, N Engl J Med, 358, 1663, 10.1056/NEJMoa0707056
Bolis, 2004, Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial, J Clin Oncol, 22, 686, 10.1200/JCO.2004.03.017
Omura, 2003, Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study, J Clin Oncol, 21, 2843, 10.1200/JCO.2003.10.082
Pignata, 2008, A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study, Crit Rev Oncol Hematol, 66, 229, 10.1016/j.critrevonc.2007.12.005
Klauber, 1997, Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol, Cancer Res, 57, 81
Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108
Sugiyama, 2000, Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy, Cancer, 88, 2584, 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5